Effectiveness of a Community-delivered Integrated Malaria Elimination (CIME) Model in Myanmar

Evaluation of the Effectiveness and Cost-effectiveness of a Community-delivered Integrated Malaria Elimination (CIME) Model in Myanmar: An Open Stepped-wedge Cluster-randomised Controlled Trial

In Myanmar, community health workers, known as malaria volunteers, have played a key role in reducing the malaria burden in the malaria control phase, providing essential malaria services in rural areas where the coverage of formal health services is limited. However, the community-delivered models that have worked well for malaria control may not work well for malaria elimination. In parallel with switching from interventions for malaria control to those for elimination, the motivation and social importance of malaria volunteers has declined along with the decline of the malaria burden. To sustain volunteer motivation, the social importance and effectiveness in the malaria elimination program, the Community-delivered Integrated Malaria Elimination model for Myanmar (CIME model) was developed based on global evidence and qualitative consultations with community members, leaders, volunteers and health stakeholders in Myanmar. This study will assess the level of effectiveness of the CIME model in increasing malaria testing by its application in an open cluster-randomised controlled stepped-wedge trial.

Study Overview

• Status: Unknown
• Conditions: Malaria
• Intervention / Treatment: Other: Community-delivered Integrated Malaria Elimination (CIME) intervention model

Detailed Description

The CIME model integrates interventions for malaria, dengue, tuberculosis, childhood diarrhoea and Rapid Diagnostic Test (RDT)-negative fever. It will involve the recruitment and training of a volunteer to implement the CIME model in each village.

The primary outcome of the trial is blood examination rate as determined by number of RDTs for malaria performed per week per village. 140 villages in 8 townships across Ayeyarwaddy, Bago and Yangon Regions and Kayah State in Myanmar will be sampled at random with probability proportional to size. Study populations include villages with ICMVs who will be re-trained as CIME volunteers (intervention phase) and the community members in the service catchment areas of those volunteers. An open stepped-wedge cluster-randomised controlled trial, randomized at the volunteer level (i.e. the volunteer and the village / workplaces they service), will be conducted over 6-months to evaluate the effectiveness and cost-effectiveness of the CIME model intervention. The stepped-wedge design will comprises 24 weekly measurements of the number of malaria blood examinations performed by each village, with villages grouped into 10 blocks of 14 villages and transitioned from control to intervention phases at bi-weekly intervals following a universal two-week control period. Differences in the per weekly rate of blood examination (primary outcome), will be estimated across intervention and control phases using a generalised linear (e.g. Poisson or negative-binomial link functions) mixed modelling analytical approach with maximum likelihood estimation.

• Study Type: Interventional
• Enrollment (Anticipated): 6440
• Phase: Not Applicable

Contacts and Locations

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: ADULT; OLDER_ADULT; CHILD
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Villages in Ayeyarwaddy, Bago and Yangon Regions and Kayah State townships in Myanmar with National Malaria Control Program (NMCP) trained Integrated Community Malaria Volunteers (ICMVs).

Exclusion Criteria:

• Townships

A township will be excluded from the study if:

1. The township does not have an NMCP provided ICMV network
2. The township has ongoing armed conflict
3. The township does not have Vector-Borne Diseases Control (VBDC) staff or malaria focal person
4. The location of the township is not geographically or politically feasible for staff from the State/Regional capital city to conduct regular supervision visits

Villages

After selection of 8 townships (2 townships from each state/region), villages in the townships will be screened against the exclusion criteria. A village will be excluded from the study if:

1. The village is too remote and unable to execute the CIME model completely,
2. The village has a government public health facility,
3. The village has no mobile network coverage
4. The village is in the ongoing armed conflict zone , or
5. The village has an ICMV program operated by any organizations other than NMCP
6. The village has an Annual Parasite Index (API) >=5

Study Plan

How is the study designed?

Design Details

• Primary Purpose: HEALTH_SERVICES_RESEARCH
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: CIME intervention; Community-delivered Integrated Malaria Elimination (CIME). The CIME intervention model integrates interventions for malaria, dengue, tuberculosis, childhood diarrhoea and RDT-negative fever.	Other: Community-delivered Integrated Malaria Elimination (CIME) intervention model; Malaria: Malaria Diagnosis using RDT, treatment, referral and reporting; Prevention interventions (Behavioral Change Communication, net and repellent distribution); assisting in case and foci investigation and larval source management. Dengue: Assisting in dengue prevention; Referral of cases. Tuberculosis (TB): Detection and referral of suspected cases; Contact tracing; Directly observed treatment, short-course (DOTS) providers; defaulter tracing; follow-up sputum examinations; assisting in TB health education talks and active case detection activities. Childhood diarrhea: Prevention; Health education and Water, sanitation and hygiene (WASH) promotion; Diagnosis and dehydration assessment; Treatment and referral; Rehydration therapy using Oral Rehydration Solution (ORS) and oral Zinc tablet; assisted referral. RDT-negative fever: Prevention and health education; Symptomatic treatment with antipyretics and immediate assisted referral.
NO_INTERVENTION: ICMV standard of care; Integrated Community Malaria Volunteer (ICMV) model - this is the current standard of care. This model involves malaria volunteers undertaking additional screening and referral services for a range of other diseases including: dengue, lymphatic filariasis, tuberculosis, HIV/AIDS and leprosy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blood examination rate	Change in blood examination rate as determined by the number of rapid diagnostic tests (RDTs) for malaria performed per week per village	Assessed weekly, longitudinally over 6-months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasmodium spp. infection detected by RDT	Change in the number of Plasmodium spp. infections detected by RDT per week per village	Assessed weekly, longitudinally over 6-months.
Plasmodium spp. infections reported with 24 hours	Change in the number and percentage of Plasmodium spp. infections reported within 24 hours of RDT per village	Assessed weekly, longitudinally over 6-months.
Plasmodium spp. infection detected by PCR	Change in the number of Plasmodium spp. infections detected by polymerase chain reaction (PCR) (from RDT cassette) per week	Assessed weekly, longitudinally over 6-months.
Larval source management	Change in the number of larval sources managed by the volunteer per week	Assessed weekly, longitudinally over 6-months.
Dengue cases	Change in the number of suspected Dengue cases referred to the nearby clinic per week	Assessed weekly, longitudinally over 6-months.
Tuberculosis (TB) cases	Change in the number of suspected tuberculosis cases referred for diagnosis to national tuberculosis program per week	Assessed weekly, longitudinally over 6-months
TB DOTS	Number of TB patients monitored by volunteer for DOTS over the whole study period	6-month
Diarrheal cases diagnosed, treated and referred	Change in the number of diarrheal cases diagnosed, treated with ORS and zinc tablets and referred per week	Assessed weekly, longitudinally over 6-months
RDT-negative fever cases	Change in the number of RDT-negative fever cases referred per week	Assessed weekly, longitudinally over 6-months
Malaria treatment according to national policy	Change in the proportion of patients with confirmed malaria who received first-line antimalarial treatment according to national policy	Assessed weekly, longitudinally over 6-months
Data accuracy and completeness in reporting of malaria cases	Change in the number of accurately reported and complete malaria case records according the national malaria case-based reporting format	Assessed weekly, longitudinally over 6-months
Malaria drug resistance-associated mutations	Change in the proportion of Kelch13 and other resistance mutations detected by PCR from RDT cassettes	Assessed weekly, longitudinally over 6-months
Seroprevalence of malaria-associated antibodies	Change in the seroprevalence of anti-malarial antibodies detected by enzyme-linked immunosorbent assay (ELISA) from RDT cassette	Assessed weekly, longitudinally over 6-months
Levels of malaria-associated antibodies	Change in the levels of anti-malarial antibodies detected by enzyme-linked immunosorbent assay (ELISA) from RDT cassette	Assessed weekly, longitudinally over 6-months
Acceptability of the CIME model by villagers	Acceptability of the CIME model by villagers assessed by an investigator-developed questionnaire including component constructs such as affective attitude, burden, perceived effectiveness and self-efficacy.	6-month
Acceptability of the CIME model by CIME volunteers	Acceptability of the CIME model by CIME volunteers assessed by an investigator-developed questionnaire including component constructs such as affective attitude, burden, perceived effectiveness and self-efficacy.	6-month
Acceptability of the CIME model by stakeholders	Acceptability of the CIME model by stakeholders assessed by focus group discussions.	6-month
Cost-effectiveness of the CIME model	Cost-effectiveness of the CIME model compared to ICMV model (Cost per unit detection, treatment and notification of a malaria case)	6-month

Collaborators and Investigators

• Sponsor: Macfarlane Burnet Institute for Medical Research and Public Health Ltd
• Collaborators: National Malaria Control Program, Myanmar
• Investigators: Principal Investigator: Freya Fowkes, DPhil, Burnet Institute; Principal Investigator: Win Han Oo, PhD, Burnet Institute

Publications and helpful links

General Publications

• Oo WH, Thi A, Htike W, Agius PA, Cutts JC, Win KM, Yi Linn NY, Than WP, Hkawng GN, Thu KM, Oo MC, O'Flaherty K, Kearney E, Scott N, Phyu PP, Htet AT, Myint O, Lwin Yee L, Thant ZP, Mon A, Htike S, Hnin TP, Fowkes FJI. Evaluation of the effectiveness and cost effectiveness of a Community-delivered Integrated Malaria Elimination (CIME) model in Myanmar: protocol for an open stepped-wedge cluster-randomised controlled trial. BMJ Open. 2021 Aug 13;11(8):e050400. doi: 10.1136/bmjopen-2021-050400.

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): January 1, 2021
• Primary Completion (ANTICIPATED): July 1, 2021
• Study Completion (ANTICIPATED): July 1, 2021

Study Registration Dates

• First Submitted: December 19, 2020
• First Submitted That Met QC Criteria: January 3, 2021
• First Posted (ACTUAL): January 5, 2021

Study Record Updates

• Last Update Posted (ACTUAL): January 5, 2021
• Last Update Submitted That Met QC Criteria: January 3, 2021
• Last Verified: January 1, 2021

More Information

Terms related to this study

• Keywords: Intervention; vivax; falciparum; elimination; Community-delivered; routine testing; Stepped-wedge
• Additional Relevant MeSH Terms: Infections; Vector Borne Diseases; Parasitic Diseases; Protozoan Infections; Malaria
• Other Study ID Numbers: 241/20_CIME_Malaria

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified individual participant data will be available after publication from the data custodian(s) to applicants who provide a sound proposal to The Ethics Review Committee on Medical Research Involving Human Subjects, Department of Medical Research, Myanmar Ministry of Health and Sports (No. 5 Ziwaka Road, Dagon PO Yangon, Myanmar; (+95) 01 375447 extension 118; ercdmr2015@gmail.com) contingent of their approval.
• IPD Sharing Time Frame: Supporting information will be published in peer-reviewed journals within 2 years of study completion.
• IPD Sharing Access Criteria: Supporting information can be requested from study investigators
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No